@JohnGolf_CA MoA undisclosed. There's not necessarily any difference between the two - $RHHBY often gives 2 or 3 codes to each NME. I'm still not sure these two are the same though.
$RHHBY RG6735 = RO7851624 perhaps? New ct-gov listing -> https://t.co/7HDnRptHHS
Any idea what RG6735 is? Looks like a new $RHHBY code for sth that went into phase 1 earlier under a different name. https://t.co/7Cb5Ft2BWC
@NotGenentech $NVS Piqray now seems like yesterday's tech. Toxic, and hits wild-type. Same for $RHHBY Itovebi (despite the bizarre claim that that's a degrader).
Since my 2024 look at CCR8 a lot has happened: $BMY $GILD $ABBV upsized; $ONC Bayer $ZLAB (& soon $AMGN?) discontinued. @BatirtzeAreitio investigates, via @ApexOnco -> https://t.co/hUweyScpAN $CHRS $RHHBY
In hindsight the ESR1m FDA outcome in the 2nd line should have been obvious to anyone with a basic knowledge of the science here. I expected it to work 1st-line, but it didn't (bad luck?). And it shouldn't have worked in adjuvant ( $RHHBY got lucky?).
In summary then, $RHHBY giredestrant: - works in adjuvant - doesn't work 1st-line - works in all-comers 2nd-line (but FDA says it only works in ESR1m) Crystal clear!
We know $ARVN is no different, and I doubt $OLMA will be. You can game a trial, but you can't really circumvent basic science $AZN $RHHBY $LLY
FDA calls BS on $RHHBY's giredestrant all-comers claim. Via @BatirtzeAreitio at @ApexOnco -> https://t.co/tTOfxpfowa
So basically just as @ByMadeleineA wrote at #ESMO25 $RHHBY https://t.co/oyjFX9CA0T https://t.co/EWbL9NFgvr
So after all that, giredestrant is just like any other oral SERD. #sadtrombone for $RHHBY https://t.co/qIbkcVbBBH
Meanwhile, a new $RHHBY anti-B7-H3 ADC is listed in phase 1. Presumably that's tambotatug pelitecan, licensed from Medilink a few weeks ago https://t.co/lu8L5XF4ft https://t.co/W7rG9AuUYz
$RHHBY discontinued RG6561 / RO7759065, which started phase 1 in Aug 2024. Mechanism still undisclosed https://t.co/VDxU8BSzNv
...while ATR inhibition fails again. No surprise there TBH https://t.co/LNra4muDj0 $AZN $RPTX $MKGAF $RHHBY
@NotGenentech @bioinvestor24 Here's a list of just the clinical pan-RAS & pan-KRAS assets from Oncologypipeline $RVMD $LLY $ONC $RHHBY $PFE $ERAS $AZN $AMGN $ALPMF https://t.co/oeb4Yr2nzo
Shock! $LLY reveals Inluriyo + Verzenio combo filing in ESR1m only, despite showing #SABCS25 promise in ESR1w/t. Scoop via @ApexOnco -> https://t.co/gUDeeMpmXb $RHHBY $AZN $ARVN $OLMA
So where does this the #tigit Fc debate? Fc-active: $GSK $ITOS fail, $MRK fail, $RHHBY fail Fc-silent: $RCUS $GILD fail Fc-reduced: $AZN $CGEN ?
After $RHHBY #Tigit failed in Skyscraper-14 $RCYS $GILD terminate Star-221 for futility. Evidently someone was surprsed as $RCUS is -12% PM
@MarkYarchoan I need to doublecheck, but I think $AZN rivegostomig total recruitment target might now be higher than $RHHBY's for tiragolumab. Just amazing.
Who won #ESMO25 and who lost? Via @ApexOnco https://t.co/EWzHIIH1Ck $IOBT $CELC $RCUS $CGEM $IDYA $NUVL $AGEN $GILD $DSNKY $INCY $CATX $LPTX $OLMA $SMMT $AVBP $GMAB $EXEL $CGEN $ZLAB $RHHBY
A #tigit postmortem from $RHHBY at #ESMO25. Tic toc $RCUS. Via @ApexOnco -> https://t.co/UOtLHj3eqY
Now on to $RHHBY Skyscraper-09, 1st-line PD-L1≥5% squamous head & neck. Data actually don't look terrible, but ph2 study was pretty small, and not powered to compare #tigit vs control (ORR primary). Via Amanda Psyrri #ESMO25 https://t.co/pCR12uogiy
Tubulis succeeds in Napi2b where $MRSN $RHHBY & $ZYME failed. Via @ApexOnco from #ESMO25: https://t.co/NqcAJZMnK9
More statistical geekery from $RHHBY #tigit studies (FWIW): alpha allocation in Imbrave-152 #ESMO25 https://t.co/BqQnhL5E4X
$RHHBY #tigit post-mortem continues with Imbrave-152 data in 1L liver cancer. No OS curves, but OS said by Richard Finn to be immature and not expected to reach stat sig, with HR=0.94 (CI 0.7-1.2) #ESMO25 https://t.co/ee06KVp4LV
What's Tubulis's Napi2b ADC secret sauce? 50% cORR with TUB-040, per Antonio González-Martín $MRSN $RHHBY $ZYME #ESMO25 https://t.co/75tOveLybZ
How did $AZN Potomac readout match $PFE Crest almost number for number? Plus a #sadtrombone for Tecentriq in $RHHBY Alban, from #ESMO25 yesterday via @ApexOnco -> https://t.co/twVmLvjhMv
Meanwhile, here's Skyscraper-03, stage III NSCLC. #tigit combo is no better than Imfinzi, but adds tox. No attempt by Rafal Dziaduszko to gloss over how bad these data are #ESMO25 $RHHBY $RCUS $GILD $AZN https://t.co/ACHpJ4614l
How bad was $RHHBY Skyscraper-07? Adding Tigit to PD-L1 + chemo actually shortened survival (prob owing to more AEs). Question now: does Tecentriq + chemo (without tira) have a future in this setting? #ESMO25 https://t.co/0ZFsjZPhB7
#ESMO25 LBA16 = giredestrant Evera $RHHBY https://t.co/YkHZuKBhz3 https://t.co/leo79XnfLd
$IOBT (-75% this am), $LPTX, $CELC & some other #ESMO25 late breakers, via @ApexOnco https://t.co/FAEqm9otw5 $EXEL $RHHBY $AZN
Kudos to $RHHBY for not trying to bury its Tigit failures. 4 pivotal trials will feature at #ESMO25, incl 2 late-breakers & Imbrave-152. Via @ApexOnco -> https://t.co/8rgBs3O2Wy $RCUS $GILD $AZN $MRK $GSK
Apparently #SITC25 is hosting a webinar on development of anti-CCR8 MAbs - mechanisms & clinical results. 22 Oct 2025 $CHRS $BMY $ABBV $RHHBY $AMGN $GILD $BGNE $FGEN $BNTX
Looks like a terrific #ESMO25 coming up for $RHHBY: Imbrave-152, Skyscraper-03 (both late-breakers), Skyscaper-07 & Skyscraper-09 all being presented!
Interesting take on the FcRH5 landscape, which seems to be one of $RHHBY's main oncology R&D areas of interest. $MRNA & $LEGN active here https://t.co/87JPjuwyu5
"Combination" doing a lot of heavy lifting for $RHHBY https://t.co/qj6iiQWYsm
Those trumpeting $RHHBY giredestrant's apparent win in all-comers have rather short memories, no? (Remember Emerald was, like Evera, enriched for ESR1m disease.) https://t.co/AztcE1Hg8I
Live tweets from $RHHBY pharma day today via @ByMadeleineA
FDA appears not to have published these recent CRLs (or have I missed them??): Linvoseltamab $REGN Datroway $AZN $DSNKY Talzenna $PFE Columvi $RHHBY
Looking for X-trial comparisons for the $TIL ImmuneOnco data? $RHHBY Impower-150 is one, and here's another: Akeso ph2 ORRs for ivonescimab + chemo from #ELCC24 $SMMT https://t.co/HRqz3MDiff
Europe moves to reject embattled Duchenne muscular dystrophy gene therapy https://t.co/jrKJVuY9ck via @DrewQJoseph $RHHBY $SRPT
@jq1234t Do you think $RHHBY will ever present full Sky-14 data?
I see KSQ has updated its R&D pipeline for the loss of $RHHBY as a partner on USP1. Autoimmune use is new though, right? https://t.co/nr9bkhWiFu
Via Tony Ren @ Macquarie: $RHHBY decision to discontinue eciskafusp alfa is not an endorsement of IL-2, α-biased or otherwise. We had argued that $IVBXF IBI363 outlicencing expectation is so high that anything short of a mega deal (at least $300-500m up front) could disappoint.
@sciencescanner @adamfeuerstein Two rivals, $RHHBY & $MRK, simultaneously seeing promise and launching ph3, then trying to outdo each other in secret. When the curtain lifted both were in huge pivotal programmes, and having dug a hole this deep they felt they couldn't stop. A bit like HS2 really.
5,000 patients later $RHHBY finally dumps its #tigit (Sky-14 is quietly said to have failed). Via @ApexOnco -> https://t.co/nAdoMmG6tI $RCUS $GILD $AZN https://t.co/ufrJGMzbh1
$RHHBY Skyscraper-14 / Imbrave-152 "primary PFS endpoint not met in Q2 2025; no trend to OS benefit observed". Buried in the slide deck #tigit
Here's the big shocker (or not?) though: $RHHBY discontinued Skyscraper-14 / Imbrave-152, its only remaining hope for tiragolumab #tigit https://t.co/m3Jjl5kyl6
Has KSQ been told? $RHHBY https://t.co/nxqpd3Mp4P
Meanwhile, $RHHBY Q2 discontinuations: Eciskafusp alfa (PD1-IL2v FP) cf $IVBXF RG6614 (RO7623066 KSQ USP1 inhibitor disappointed at #ASCO24) $EXEL $TNGX [RG6457 / RO7589831 WRNi, disclosed earlier] https://t.co/RPEvWDSVPK
Aha, looks like $RHHBY RG6505 = RO7673396 https://t.co/6jlSuF6633
$RHHBY into phase 1 with a new pan-Ras inhibitor? RG6505 can't be the same as LUNA18 (via Chugai's Epoc acquisition) as that started ph1 in 2021 $RVMD https://t.co/TIy7yIk8mH
Guess who's about to take a SC anti-PD-1 into phase 3? Via @ApexOnco -> https://t.co/TNXStCSSIo $ONC $BGNE $RHHBY $AZN $MRK $BMY $PFE
#ESMOGI25 $REGN $GSK $RHHBY $COGT $REPL
A new CDK2 degrader, plus $KYMR's return to oncology. Via @ApexOnco -> https://t.co/9iW8otUzvn $GILD $PFE $INCY $RHHBY $GLUE $BPMC
Here we go: 10% of Sunmo patients were from North America, 38% from Asia $RHHBY #ICML2025 https://t.co/QwHBaHOTA8
Impressive data for Lunsumio + Polivy in Sunmo. But I wonder if $RHHBY is about to run into the same problem here as it did in Starglo with Columvi: Sunmo comprised 4 US hospitals, 3 Canada, 5 Mex, 11 S Am, 6 China, 2 Israel, 6 Japan, 6 Korea, 1 NZ, 4 Thailand, 5 Turkey
Surprising that $NUVB Ibtrozi has been allowed as the tradename. Fairly similar to $RHHBY Itovebi, no?
Is $BMY BMS-986500 a CDK2 inhibitor? https://t.co/0GKMRRiKLm $PFE $RHHBY https://t.co/0NCG2palqG
@NotGenentech The $RHHBY Vividion data is the only clinical Werner one I can see at #AACR25. Preclinical stuff only on Nimbus, $NVS etc.
$RHHBY dumps Werner helicase. Over to $GSK, $NVS, Nimbus & Moma. Via @ApexOnco -> https://t.co/nrFQP64eMR https://t.co/KiDoTjHV3y
